natgillin/translations-raw huggingface dataset:
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. 
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki daje zdravilo živalim V primeru nenamernega samoinjiciranja se takoj posvetujte z zdravnikom in mu pokažite navodilo za uporabo ali nalepko na zunanji ovojnini.
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY 
POSEBNI PREVIDNOSTNI UKREPI ZA ODSTRANJEVANJE NEPORABLJENEGA ZDRAVILA ALI ODPADNIH SNOVI, ČE OBSTAJAJO
Primary vaccination: Sows/gilts which have not yet been vaccinated with the product are given a primary injection 6 to 8 weeks before the expected date of farrowing and a second injection 4 weeks later. 
Shema cepljenja: Prvo cepljenje: Svinjam oz. mladicam, ki še niso bile cepljene, se prvi odmerek cepiva da 6 do 8
100 ml (50 doses) 200 ml (100 doses) 250 ml (125 doses) 
100 ml (50 odmerkov) 200 ml (100 odmerkov) 250 ml (125 odmerkov)
20 ml (10 doses) 50 ml (25 doses) 100 ml (50 doses) 200 ml (100 doses) 250 ml (125 doses) 
20 ml (10 odmerkov) 50 ml (25 odmerkov) 100 ml (50 odmerkov) 200 ml (100 odmerkov) 250 ml (125 odmerkov)
Lot 
Brejost
Escherichia coli components: - F4ab fimbrial adhesin 
Komponente E. coli: - fimbrijski adhezin F4ab
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALEC (IZDELOVALCI) BIOLOŠKE ZDRAVILNE UČINKOVINE (ZDRAVILNIH UČINKOVIN) IN IMETNIK(I) DOVOLJENJ(A) ZA IZDELAVO ZDRAVILA, ODGOVOREN (ODGOVORNI) ZA SPROSTITEV SERIJE
Per dose of 2 ml: E. coli: F4ab fimb. 
V odmerku po 2 ml: E. coli: fimbrijski adhezin F4ab fimbrijski adhezin F4ac fimbrijski adhezin F5
Adjuvant: dl-α-tocopheryl acetate 
Dodatek dl-α-tokoferilacetat
Marketing authorisation holder: 
V postmarketinškh izkušnjah:
Cardboard box with a vial of 20, 50, 100, 200 or 250 ml 
Kartonska škatla z vialo po 20, 50, 100, 200 ali 250 ml
- F5 fimbrial adhesin 
- fimbrijski adhezin F5
4.8 Interaction with other medicinal products and other forms of interaction 
4.8 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Ni podatkov o varnosti in učinkovitosti ob uporabi tega cepiva s katerim koli drugim zdravilom za uporabo v veterinarski medicini.
Aqueous, white to nearly white suspension for injection. 
Vodna, bela do skoraj bela suspenzija za injiciranje za prašiče Vsak odmerek po 2 ml vsebuje:
IM 
C .
PARTICULARS TO APPEAR ON THE OUTER PACKAGE BOX 
PODATKI NA ZUNANJI OVOJNINI ¸ ŠKATLA
Immunological properties of the product: To stimulate active immunity in order to provide passive immunity to the progeny against enterotoxicosis caused by E. coli expressing fimbrial adhesins F4ab (K88ab), F4ac (K88ac), F5 (K99), F6 (987P) and against (necrotic) enteritis caused by C. perfringens type C. 
Cepivo za spodbujanje aktivne imunosti svinj oz. mladic za razvoj pasivne imunosti potomcev proti enterotoksikozi, ki jo povzročijo sevi E. coli, ki izločajo fimbrijske adhezine F4ab (K88ab), F4ac
Cardboard box with a PET vial of 20, 50, 100, 200 or 250 ml. 
Kartonska škaltla z vialo iz PET z 20, 50, 100, 200 ali 250 ml.
- F6 fimbrial adhesin 
- fimbrijski adhezin F6
Cardboard box with a glass vial of 20, 50, 100 or 250 ml. 
Velikosti pakiranj: Kartonska škatla s stekleno vialo z 20, 50, 100 ali 250 ml.
WITHDRAWAL PERIOD 
DATUM IZTEKA ROKA UPORABNOSTI
To stimulate active immunity in order to provide passive immunity to the progeny against enterotoxicosis caused by E. coli expressing fimbrial adhesins F4ab (K88ab), F4ac (K88ac), F5 (K99), F6 (987P) and against (necrotic) enteritis caused by C. perfringens type C. Vaccination results in an antibody response with neutralizing activity against LT toxin. 
(K88ac), F5 (K99), F6 (987P), in proti (nekrotičnemu) enteritisu, ki ga povzroča tip C C. perfringens.
- F4ac fimbrial adhesin 
- fimbrijski adhezin F4ac
Name and address of the manufacturers of the biological active substances 
Ime in naslov izdelovalcac biološke zdravilne učinkovine Intervet International B.V.
Polysorbate 80 
Polisorbat 80 voda za injekcije
For animal treatment only. 
Samo za živali -Rp-Vet.
Cardboard box with PET vial of 20 ml, 50 ml, 100 ml, 200 ml or 250 ml. 
Kartonska škatla z vialo iz PET po 20 ml, 50 ml, 100 ml, 200 ml ali 250 ml Kartonska škatla z vialo iz stekla tipa I po 20 ml, 50 ml, 100 ml ali 250 ml Viale so zaprte z zamaškom iz halogenbutilne gume in zavarjene z aluminijasto zaporko.
Withdrawal period: Zero days 
KARENCA Karenca: Nič dni
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE VIAL LABEL 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA STIČNIH OVOJNINAH
Date of first authorisation: 16 December 2014 Date of latest renewal: 
Datum prve odobritve: 16. december 2014 Datum zadnjega podaljšanja:
This applies to the following medicines: 
To velja za naslednja zdravila:
Regularly check your breasts. 
Redno si pregledujte dojke.
This medicine is not for use in children and adolescents below 18 years old. 
To zdravilo ni namenjeno za uporabo pri otrocih in mladostnikih, mlajših od 18 let.
• if you have cancer. 
• če imate raka.
Therapy should then be continued as before. 
Nato mora zdravljenje nadaljevati enako kot prej.
See your doctor as soon as possible if you notice any changes, such as: 
Čimprej obiščite zdravnika, če opazite kakršnekoli spremembe, kot so:
The occurrence of such a reaction is more likely in the first year of treatment. 
Pojav take reakcije je verjetnejši v prvem letu zdravljenja.
The data from the largest randomised trial are summarised below: 
Podatki iz največjega randomiziranega preskušanja so povzeti spodaj:
Treatment should not be restarted until the woman is completely mobilised. 
Zdravljenja se ne sme začeti znova, dokler bolnica ni povsem mobilna.
Ask your doctor when you can start taking this medicine again. 
Vprašajte zdravnika, kdaj lahko ponovno začnete jemati to zdravilo.
• if you are seriously overweight (BMI >30 kg/m 
• če ste izrazito pretežki (ITM > 30 kg/m
You are advised to: 
Svetujemo vam, da:
Do not take this medicine if you are pregnant, or if you think you might be pregnant. 
Ne jemljite tega zdravila, če ste noseči ali mislite, da bi lahko bili noseči.
The extra risk depends on how long you take HRT. 
To dodatno tveganje je odvisno od tega, koliko časa uporabljate HNZ.
Tell your doctor if you have any medical problems or illnesses. 
Povejte zdravniku, če imate kakršnekoli zdravstvene težave ali bolezni.
In order for this medicine to work, it should be taken daily as prescribed. 
Da bo zdravilo delovalo, ga morate jemati vsak dan, kot je predpisano.
There is no evidence that HRT will prevent a heart attack. 
Ni dokazov, da bo HNZ preprečilo srčno kap.
The risk ratio is not constant but will increase with increasing duration on use. 
Razmerje tveganja ni konstantno, ampak se veča z daljšanjem časa uporabe.
Once you have started this medicine you should see your doctor for regular check-ups (at least once a year). 
Ko začnete uporabljati to zdravilo, morate obiskovati zdravnika zaradi rednih pregledov (vsaj enkrat na leto).
In all cases, a careful appraisal of the risks and benefits should be undertaken at least annually, and treatment should only be continued as long as the benefit outweighs the risk. 
V vsakem primeru je treba vsaj enkrat na leto natančno oceniti tveganja in koristi, zdravljenje pa se lahko nadaljuje le, če so koristi večje od tveganja.
Relief of menopausal symptoms was achieved during the first few weeks of treatment. 
Lajšanje menopavzalnih simptomov so dosegli v prvih nekaj tednih zdravljenja.
Reasons for immediate withdrawal of therapy 
Razlogi za takojšnjo prekinitev zdravljenja
• any lumps you can see or feel 
• kakršnekoli zatrdline, ki jih lahko vidite ali začutite.
No overall differences in safety or efficacy were observed between women aged >65 years and younger women, but greater sensitivity of some older individuals cannot be ruled out. 
Med ženskami, starimi > 65 let in mlajšimi, na splošno niso opazili razlik v varnosti ali učinkovitosti, vendar večje občutljivosti nekaterih starejših žensk ni mogoče izključiti.
• Painful red bumps on the skin 
• boleče rdeče bule na koži;
If you notice any of the following: 
Če opazite karkoli izmed spodaj navedenega:
Other things that can increase the risk of stroke include: 
Drugi dejavniki, ki lahko zvečajo tveganje za možgansko kap, vključujejo:
Your doctor will aim to prescribe the lowest dose to treat your symptom for as short as necessary. 
Zdravnik vam bo poskusil predpisati najmanjši odmerek za zdravljenje vašega simptoma, ki naj bi bilo čim krajše.
These findings are considered rat-specific and presumably not relevant in humans. 
Te ugotovitve so specifične za podgane in domnevno niso pomembne za ljudi.
The experience treating women older than 65 years is limited. 
Izkušnje z zdravljenjem žensk, starejših od 65 let, so omejene.
Free T4 and free T3 concentrations are unaltered. 
Koncentraciji prostega T3 in T4 se ne spremenita.
The relative risk does not change with age or time since menopause. 
Relativno tveganje se ne spremeni s starostjo ali časom od menopavze.
Call your doctor or pharmacist. 
Pokličite zdravnika ali farmacevta.
Speak to your doctor for advice. 
Za nasvet se posvetujte z zdravnikom.
• Difficulty wearing contact lenses 
• težave pri nošenju kontaktnih leč.
• Discolouration of the skin on the face or other parts of the body 
• obarvanje kože na obrazu ali drugih delih telesa;
DUAVIVE is used for: 
Zdravilo DUAVIVE se uporablja za:
Women should be advised what changes in their breasts should be reported to their doctor or nurse (see ‘Breast cancer' below). 
Ženskam je treba svetovati, o katerih spremembah na dojkah morajo poročati zdravniku ali medicinski sestri (glejte »Rak dojke« spodaj).
Serious venous thromboembolic events may occur rarely (less than 1 case per 1,000 patients). 
Redko se lahko pojavijo resni venski trombembolični dogodki (manj kot 1 primer na 1.000 bolnic).
No foetal developmental anomalies were observed. 
Razvojnih anomalij plodov niso opazili.
EU/1/14/960/001 28 tablets 
EU/1/14/960/001 28 tablet
You can take the tablet at any time of the day, with or without food; however, it is advisable to take your tablet at the same time each day as this will help to remind you to take your medicine. 
Tableto lahko vzamete kadarkoli v dnevu, s hrano ali brez nje, priporočamo pa, da jo vzamete vsak dan ob istem času, saj si boste tako lažje zapomnili, da jo morate vzeti.
This might lead to irregular bleeding. 
To lahko privede do neobičajne krvavitve.
This may include an examination of your breasts and/or an internal examination, if necessary, or if you have any special concerns. 
Morda se bo odločil opraviti telesni pregled, ki lahko vključuje pregled dojk in/ali notranji pregled, če je potreben, ali če imate kakršnekoli posebne skrbi.
• drinking too much alcohol 
• pretirano pitje alkohola;
If you feel drowsy after taking this medicine, you should avoid driving or operating machines. 
Če po jemanju tega zdravila občutite dremavost, se morate izogibati vožnji ali upravljanju strojev.
You will only be prescribed this medicine if your symptoms seriously hinder your daily life and your doctor determines that other types of HRT are not appropriate for you. 
To zdravilo vam bodo predpisali samo, če vas simptomi resno ovirajo pri vsakdanjem življenju in če vaš zdravnik ugotovi, da druge oblike hormonskega nadomestnega zdravljenja (HNZ) za vas niso primerne.
• migraine-like headaches which happen for the first time 
• glavobole, podobne migreni, ki se pojavijo prvič;
Investigations, including appropriate imaging tools, e.g., mammography, should be carried out in accordance with currently accepted screening practices, modified to the clinical needs of the individual. 
Preiskave, vključno s slikanjem z ustreznimi orodji (npr. mamografijo), je treba opraviti skladno s trenutno veljavno prakso za presejalne preglede, prilagojeno kliničnim potrebam posameznice.
• if you have systemic lupus erythematosus (SLE). 
• če imate sistemski eritematozni lupus (SLE);
The use of DUAVIVE carries risks, which need to be considered when deciding whether to start taking it, or whether to carry on taking it. 
Uporaba zdravila DUAVIVE vključuje tveganja, ki jih je treba upoštevati pri odločitvi, ali boste začeli jemati to zdravilo in ali boste jemanje nadaljevali.
CE/BZA was evaluated in 4,868 post-menopausal women who participated in 5 phase 3 trials. 
Kombinacijo CE/BZA so ocenjevali pri 4.868 ženskah v postmenopavzi, ki so sodelovale v 5 preskušanjih 3. faze.
Stop taking DUAVIVE and see a doctor immediately 
Prenehajte jemati zdravilo DUAVIVE in takoj obiščite zdravnika
If you forget to take a tablet, take it as soon as you remember. 
Če pozabite vzeti tableto, jo vzemite takoj, ko se spomnite.
• if you have any blood clotting problem that needs long-term treatment with a medicine used to prevent blood clots 
• če imate kakršnokoli težavo s strjevanjem krvi, ki zahteva dolgotrajno zdravljenje z zdravilom za preprečevanje krvnih strdkov;
• if you are unable to walk for a long time because of major surgery, injury or illness (see also section 3, if you need to have surgery) 
• če niste zmožni daljše hoje zaradi večjega kirurškega posega, poškodbe ali bolezni (glejte tudi poglavje 3 »Če vam bodo opravili kirurški poseg«);
Pfizer Ireland Pharmaceuticals, Little Connell, Newbridge, County Kildare, Ireland. 
Proizvajalec Pfizer Ireland Pharmaceuticals, Little Connell Newbridge, County Kildare, Irska.
During these check-ups, discuss with your doctor the benefits and risks of continuing with DUAVIVE. 
Pri teh pregledih se z zdravnikom posvetujte o koristih in tveganjih nadaljevanja jemanja zdravila DUAVIVE.
Some medicines may interfere with the effect of DUAVIVE. 
Nekatera zdravila lahko vplivajo na učinek zdravila DUAVIVE.
• any of the conditions mentioned under ‘Do not take DUAVIVE' 
• katerokoli bolezen, omenjeno v poglavju »Ne jemljite zdravila DUAVIVE«;
Food had little or no effect on the exposure of CE. 
Hrana je imela majhen vpliv ali sploh ni imela vpliva na izpostavljenost CE.
The major route of excretion of radiolabeled BZA is the faeces, and less than 1% of the dose is eliminated in urine. 
Glavna pot izločanja radioaktivno označenega BZA je blato, manj kot 1 % odmerka pa se izloči z urinom.
The concentrations of this glucuronide are approximately 10-fold higher than those of unchanged BZA in plasma. 
Koncentracije tega glukuronida so približno 10-krat večje kot koncentracije nespremenjenega BZA v plazmi.
Longterm exposure to CE/BZA for up to 2 years was evaluated; 3,322 women were exposed to CE/BZA for at least 1 year, and 1,999 women were exposed for 2 years. 
Ocenili so dolgotrajno izpostavljenost CE/BZA, ki je trajala do 2 leti; 3.322 žensk je bilo izpostavljenih kombinaciji CE/BZA najmanj 1 leto, 1.999 žensk pa je bilo izpostavljenih 2 leti.
During the menopause, the amount of the oestrogen produced by a woman's body drops. 
Med menopavzo se količina estrogena, ki ga proizvaja telo, zmanjša.
The level of risk is dependent on duration of use (see section 4.4). 
Stopnja tveganja je odvisna od trajanja uporabe (glejte poglavje 4.4).
If this happens, you should avoid driving or operating machines until your doctor tells you that it is safe to do so. 
Če se to zgodi, se morate izogibati vožnji ali upravljanju strojev, dokler vam zdravnik ne pove, da je to varno.
Oestrogen therapy will not prevent memory loss. 
Zdravljenje z estrogenom ne preprečuje izgube spomina.
- Porphyria. 
- Porfirija.
It is not known whether bazedoxifene is excreted in human milk. 
Ni znano, ali se bazedoksifen izloča v materino mleko.
Negligible (1%) amounts of BZA are eliminated in urine. 
Z urinom se izloči zanemarljiva (1 %) količina BZA.
This medicinal product contains sorbitol which may affect the bioavailability of other concomitantly administered medicinal products. 
To zdravilo vsebuje sorbitol, ki lahko vpliva na biološko uporabnost drugih sočasno uporabljenih zdravil.
CE/BZA can be administered with or without food. 
Kombinacijo CE/BZA se lahko daje s hrano ali brez nje.
• Increases in liver enzymes (identified in routine liver function testing) 
• zvišanje jetrnih encimov (ugotovljeno pri rutinskem testiranju jetrne funkcije);
If any of the following conditions are present, have occurred previously, and/or have been aggravated during pregnancy or previous hormone treatment, the patient should be closely supervised. 
Če se pojavi katerokoli od naslednjih bolezenskih stanj oziroma, če se je katerokoli od njih pojavilo že prej in/ali se je med nosečnostjo ali predhodnim hormonskim zdravljenjem poslabšalo, je treba bolnico skrbno nadzirati.
If more than one tablet has been forgotten, only the most recent tablet should be taken, the patient should not take double the usual dose to make up for missed tablets. 
Če je pozabila vzeti več kot eno tableto, mora vzeti samo zadnjo in ne sme vzeti dvojnega običajnega odmerka, da nadomesti pozabljene tablete.
CE/BZA may be taken at any time of day, without regard to meals (see section 5.2). 
CE/BZA se lahko jemlje kadarkoli čez dan, ne glede na obroke (glejte poglavje 5.2).
Following intravenous administration of a 3 mg dose of BZA alone, the volume of distribution is 14.7 3.9 l/kg. 
Po intravenski uporabi 3-mg odmerka samega BZA je volumen porazdelitve 14,73,9 l/kg.
Oestrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. 
Estrogeni se obsežno porazdelijo po telesu, v večjih koncentracijah pa jih je na splošno mogoče najti v ciljnih organih za spolne hormone.
BZA is extensively metabolised in women. 
BZA se pri ženskah obsežno presnavlja.
A meta-analysis from 52 epidemiological studies reported an increased risk of ovarian cancer in women currently using HRT compared to women who have never used HRT (RR 1.43, 95% CI 1.31-1.56). 
Pri metaanalizi 52 epidemioloških študij so poročali o povečanem tveganju za raka jajčnikov pri ženskah, ki trenutno uporabljajo HNZ, v primerjavi z ženskami, ki niso nikoli uporabljale HNZ (relativno tveganje 1,43, 95 % IZ 1,31-1,56).
• Memory loss (dementia) 
• izguba spomina (demenca);
If you are having an operation 
Če imate načrtovan kirurški poseg
Increases in blood pressure 
zvišanje krvnega tlaka
Like all medicines, this medicine can cause side effects, although not everybody gets them. 
Kot vsa zdravila ima lahko tudi to zdravilo neželene učinke, ki pa se ne pojavijo pri vseh bolnicah.
- Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. 
- Preobčutljivost na učinkovino ali katerokoli pomožno snov, navedeno v poglavju 6.1.
(thrombosis)' 
(tromboza)«.
Results of the largest randomised placebo-controlled trial (WHI-study) and largest epidemiological study (MWS) are presented. 
Prikazani so rezultati največjega randomiziranega, s placebom nadzorovanega preskušanja (študija WHI) in največje epidemiološke študije (MWS).
It should be taken into account that these conditions may recur or be aggravated during treatment with CE/BZA, in particular: 
Treba je upoštevati, da se med zdravljenjem s CE/BZA ta bolezenska stanja lahko ponovijo ali poslabšajo, zlasti:
In addition, women taking CE/BZA should be advised to move about periodically during travel involving prolonged immobilisation. 
Poleg tega je treba ženskam, ki jemljejo CE/BZA, svetovati, da se med potovanjem, pri katerem so dlje časa nepremične, občasno gibljejo.
However, if it is almost time to take your next tablet, skip the tablet you missed and only take your next scheduled tablet. 
Če pa je skoraj čas za naslednjo tableto, izpustite pozabljeno tableto in vzemite samo naslednjo načrtovano tableto.
The European Medicines Agency has waived the obligation to submit the results of studies with CE/BZA in all subsets of the paediatric population in the ‘treatment of oestrogen deficiency symptoms in postmenopausal women' (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od obveze za predložitev rezultatov študij s kombinacijo CE/BZA za vse podskupine pediatrične populacije za »zdravljenje simptomov pomanjkanja estrogena pri ženskah v postmenopavzi« (za informacije o uporabi pri pediatrični populaciji glejte poglavje 4.2).
In case of overdose it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment be instituted immediately. 
V primeru prevelikega odmerjanja je priporočljivo bolnico spremljati glede kakršnihkoli znakov ali simptomov neželenih učinkov in takoj uvesti ustrezno simptomatsko zdravljenje.
If you decide to stop taking this medicine before finishing the prescribed course of treatment, you should talk to your doctor first. 
Če se odločite, da boste prenehali jemati to zdravilo, preden se konča predpisano zdravljenje, se morate najprej posvetovati z zdravnikom.
In a pharmacokinetic study (n=24) BMI appeared to have little impact on systemic exposure to CE and BZA. 
V farmakokinetični študiji (n = 24) se je izkazalo, da ima ITM majhen vpliv na sistemsko izpostavljenost CE in BZA.
The occurrence of such an event is more likely in the first year of HRT than later (see section 4.8). 
Pojav takega dogodka je verjetnejši v prvem letu hormonskega nadomestnega zdravljenja (HNZ) kot pozneje (glejte poglavje 4.8).
*study in women with no uterus 
* Študija pri ženskah brez maternice
Based on available data no dosage adjustment is necessary based on age (see section 5.2). 
Na podlagi razpoložljivih podatkov prilagajanje odmerka glede na starost ni potrebno (glejte poglavje 5.2).
Oestrogen therapy use does not improve cognitive function. 
Zdravljenje z estrogeni ne izboljša kognitivne funkcije.
17β-estradiol is converted reversibly to estrone, and both can be converted to estriol, which is the major urinary metabolite. 
17β-estradiol se reverzibilno pretvori v estron, oba pa se lahko pretvorita v estriol, ki je glavni presnovek v urinu.
In vitro and in vivo studies have shown that oestrogens are partially metabolised by cytochrome P450 enzymes, including CYP3A4. 
Študije in vitro ter in vivo so pokazale, da se estrogeni delno presnavljajo preko encimov citokroma P450, vključno s CYP3A4.
Since you are more likely to get a blood clot in your veins as you get older and if any of the following applies to you, inform your doctor promptly: 
Ker je verjetnost, da bo nastal krvni strdek v venah, z naraščanjem starosti večja, in če karkoli izmed navedenega velja za vas, nemudoma obvestite zdravnika:
• go for regular breast screening and cervical smear tests, as recommended by your doctor. 
• opravite redni preventivni pregled dojk in bris materničnega vratu, kot to priporoča vaš zdravnik;
If you are going to have surgery, tell the surgeon you are taking DUAVIVE. 
Če imate načrtovan kirurški poseg, povejte kirurgu, da jemljete zdravilo DUAVIVE.
Oestrogens circulate in the blood largely bound to SHBG and albumin. 
V krvnem obtoku so estrogeni v veliki meri vezani na SHBG in albumin.
• Low levels of blood calcium (hypocalcaemia); frequently there will be no symptoms to suggest that your blood calcium is low, but when hypocalcaemia is severe you may feel tired, generally unwell, depressed and become dehydrated. 
• nizke ravni kalcija v krvi (hipokalciemija); pogosto ni opaznih simptomov, ki kažejo na pomanjkanje kalcija v krvi, vendar se pri hudi hipokalciemiji lahko počutite utrujeno, na splošno slabo, ste depresivni ali dehidrirate.
The results of most epidemiological studies to date relevant to inadvertent foetal exposure to oestrogens indicate no teratogenic or foetotoxic effects. 
Rezultati večine do sedaj opravljenih epidemioloških študij v zvezi z nenamernim izpostavljanjem zarodka estrogenom ne kažejo nobenih teratogenih ali fetotoksičnih učinkov.
Safety and efficacy have not been evaluated further in women with hepatic insufficiency. 
Varnosti in učinkovitosti pri ženskah z jetrno insuficienco niso dodatno ocenjevali.
Some other studies, including the WHI trial, suggest that use of combined HRTs may be associated with a similar or slightly smaller risk (see section 4.8). 
Nekatere druge študije, vključno s preskušanjem WHI, kažejo, da je uporaba kombiniranih HNZ lahko povezana s podobnim ali rahlo manjšim tveganjem (glejte poglavje 4.8).